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Background: During the HIV-1 replication cycle, several molecules including chemokine receptors and cholesterol
are crucial, and are therefore potential targets for therapeutic intervention. Indeed statins, compounds that inhibit
cellular synthesis of cholesterol and have anti-inflammatory and immunomodulatory properties were shown to
inhibit HIV-1 infection by R5 tropic strains but not by X4 strains in vitro, mainly by altering the chemokine receptor/
ligands axes. Therefore, the objective of this study was to characterize in vivo, the capacity of statins to modulate in
HIV seronegative and chronically HIV-1-infected adults the expression of CCR5 and CXCR4, of their ligands and the
tropism of circulating HIV-1 strains.
Methods: Samples from asymptomatic HIV-1-infected adults enrolled in a clinical trial aimed at evaluating the
antiretroviral activity of lovastatin were used to evaluate in vivo the modulation by lovastatin of CCR5, CXCR4, their
ligands, and the shift in plasma viral tropism over one year of intervention. In addition, ten HIV negative adults
received a daily oral dose of 40 mg of lovastatin or 20 mg of atorvastatin; seven other HIV negative individuals who
received no treatment were followed as controls. The frequency and phenotype of immune cells were determined
by flow-cytometry; mRNA levels of chemokine receptors and their ligands were determined by real-time PCR. Viral
tropism was determined by PCR and sequencing, applying the clonal and clinical model of analyses.
Results: Our study shows that long-term administration of lovastatin in HIV-infected individuals does not induce a
shift in viral tropism, or induce a significant modulation of CCR5 and CXCR4 on immune cells in HIV-infected
patients. Similar results were found in HIV seronegative control subjects, treated with lovastatin or atorvastatin, but
a significant increase in CCL3 and CCL4 transcription was observed in these individuals.
Conclusions: These findings suggest that long-term administration of statins at therapeutic doses, does not
significantly affect the expression of HIV-1 co-receptors or of their ligands. In addition it is important to point out
that based on the results obtained, therapeutic administration of statins in HIV-infected patients with lipid disorders
is safe in terms of selecting X4 strains.
Keywords: HIV infection, Statins, CCR5, CXCR4, Viral tropism, ChemokinesBackground
Despite the fact that highly active antiretroviral therapy
(HAART) is a clinically accepted and cost-effective inter-
vention [1], its efficiency is hampered by limitations in
therapy adherence and the emergence of viral resistance,
facts closely related to adverse effects and toxicity [2,3].
Thus, it is necessary to develop new medications and
therapeutic strategies, with novel mechanisms of action
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reproduction in any medium, provided the orHIV infection involves an initial interaction between
the viral envelope glycoprotein gp120 and the CD4
molecule on the surface of target cells, followed by a
second interaction with a co-receptor; for HIV-1, the
classical co-receptor function is provided by one of two
different molecules, the C-C chemokine receptor 5
(CCR5) or the C-X-C chemokine receptor 4 (CXCR4),
which have a normal physiological function serving as
receptors for soluble chemokines [4,5]. The critical role
of these molecules in HIV infection encouraged the de-
sign of anti-HIV drugs aimed at blocking this molecular
interaction [6-8]. Some molecules with ability to exert aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ceptor have been identified; among them, maraviroc is
the first CCR5 antagonist approved for clinical use in
HIV-infected patients, and its efficiency has been
established in clinical trials [9,10]. However, before re-
ceiving maraviroc, it is mandatory to first identify the
co-receptor used by the strains infecting each patient,
due to the risk on selecting the more pathogenic strains
that use the CXCR4 co-receptor.
On the other hand, almost every aspect of the HIV-1
life cycle relies on cholesterol [11-16]; in the absence of
this lipid, the attachment of HIV-1 to its host cells is
severely impaired because the clustering of HIV-1 receptor/
co-receptor in lipid rafts is hindered [17-19], and the
conformational status and functions of CCR5 and
CXCR4 are critically affected [18]. Indeed, in vitro stu-
dies have demonstrated that, in the absence of choles-
terol, virus-cell fusion is greatly diminished, viral
transcytosis is inhibited, production and budding of
viral particles are reduced, and cell signaling is altered
[12,20,21]. Cellular synthesis of cholesterol may be ef-
fectively inhibited by statins, medications that are com-
petitive analogues of the substrate of the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, an
enzyme that catalyzes the conversion of hydroxyl-
methyl-glutarate into mevalonic acid, a precursor for
the biosynthesis of cholesterol and isoprenoids [22-24].
Moreover, a previous in vitro study demonstrated that
CD4+ T-cell incubation with statins reduced the level of
CCR5 expression in these cells isolated from HIV negative
individuals, while it increased the secretion of its natural
ligand, RANTES (CCL5), thereby inhibiting HIV-1 infec-
tion by R5 tropic strains but no by X4 strains [25]. Conse-
quently, it is important to verify if this effect is reproducible
in vivo, mainly because statins are safe medications with
other anti-inflammatory and immunomodulatory proper-
ties, that could be of potential benefit in the treatment of
HIV-1-infected individuals [26-30].
Nevertheless, a therapy with medications that inhibit the
surface expression of CCR5 in the absence of complete
control of HIV replication, could promote the positive se-
lection of X4 strains of HIV, considered more pathogenic
[31-33]. Thus, it is important to determine if the in vivo
administration of statins promotes a change in viral trop-
ism with a shift from R5 to X4 strains of HIV-1, as this
might alter the natural course of HIV-1 infection and in-
crease the risk of rapid progression to AIDS.
This study was aimed at characterizing the in vivo cap-
acity of statins to modulate, in HIV seronegative and
chronically HIV-1 infected adults, the following parame-
ters: i) expression of the HIV-1 co-receptors CCR5 and
CXCR4, ii) levels of their ligands RANTES (CCL5),
MIP-1α (CCL3), MIP-1β (CCL4) and SDF-1 (CXCL12),
and iii) tropism of circulating HIV-1 strains.Methods
Subjects of study
Samples from chronic asymptomatic HIV-1-infected
adults enrolled in a randomized clinical trial aimed at de-
termining the antiretroviral and immunomodulatory activ-
ity of lovastatin (LIVE study, NCT00721305) [34], were
used to evaluate in vivo the modulation by lovastatin of: i)
CCR5 and CXCR4 expression on peripheral blood mono-
nuclear cells (PBMC; lovastatin group n = 41; placebo
group n = 43), and ii) the shift in plasma viral tropism
throughout one year of intervention (lovastatin n = 44;
placebo n = 47). These patients were HAART naïve, had a
detectable viral load (>50 and <100.000 RNA copies/ml)
and CD4+ T-cell counts higher than 350 cells/μl; the ex-
clusion criteria were previously defined [35].
HIV negative adults, were invited to receive a daily su-
pervised oral dose of lovastatin (40 mg/d, n = 10) or
atorvastatin (20 mg/d, n = 9); seven other individuals re-
ceived no intervention but had the same follow-up as
the intervened HIV negative controls for the steady state
variation in the expression of the HIV-1 co-receptors.
The study was conducted in accordance with the Declar-
ation of Helsinki, and the protocol was approved by the
Institutional Ethical Review Board of the University of
Antioquia. All participants provided signed informed con-
sent, prepared according to the Colombian legislation (Reso-
lution 008430 of 1993), before participating in the study.
Statins
Tablets of lovastatin (20 mg), atorvastatin (20 mg) and
placebo were kindly provided by Laproff Laboratories
(Sabaneta, Colombia). The daily dose of these interven-
tions was administered after the last meal at night, for
45 days in HIV negative controls and 360 days in HIV-
infected patients from the LIVE study. The biological ac-
tivity, safety and tolerance of statins were controlled by
clinical evaluation, pharmacotherapeutic follow-up by a
pharmacist, and by periodic testing of liver enzymes,
creatine phosphokinase (CPK) and creatinine, and by
performing a serum lipid profile. The intervention was
stopped in the presence of any serious adverse drug
event, a three-fold increase in serum hepatic amino-
transferases or a five-fold increase in CPK.
Flow cytometry protocols
The frequency and surface phenotype of CD4+ T cells and
CD3-/CD4+ monocytes in whole peripheral blood sam-
ples were determined by flow cytometry; fluorochrome-
labeled mouse monoclonal antibodies (mAbs) against
human molecules were from Becton Dickinson (BD, San
Jose, CA): CD3 FITC (clone HIT3a), CD4 APC (clone
RPA-T4), CD184 PE-Cy5 (clone 12G5), CD195 PE-Cy5
(clone 2D7/CCR5) and the corresponding isotype control
antibodies. Briefly, 150 μl of blood were incubated with
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the erythrocytes were then lysed by incubating for 10 min
with 2 ml of 1X Facs lysing solution (Becton Dickinson).
The cells were washed twice with 2 ml of cold phosphate-
buffered saline (PBS) and fixed with 250 ml of 2% parafor-
maldehyde. All the preparations were stored at 4°C until
acquisition in the cytometer FACS CANTO-II (Becton
Dickinson).
Acquisition analyses were performed using the BD
FACSDiva, version 6.1.2. Lymphocyte and monocyte
gates, identified by side (SSC) versus forward (FSC) light
scatter, were used to analyze cell populations identified
as CD3+/CD4+ and CD3-/CD4+ cells, respectively; the
surface expression of CCR5 and CXCR4 molecules was
analyzed in each cell population; dead cells were ex-
cluded from the analysis through SSC vs. FSC.
CD4+ T cell isolation and real time PCR
PBMCs were isolated from heparin anti-coagulated per-
ipheral blood by centrifugation in a Ficoll-Hypaque
(Sigma, MO) gradient; CD4+ T lymphocytes were
obtained by negative selection using the CD4+ T cell
isolation kit II (Miltenyi Biotech, Auburn, CA),
according to manufacturer’s instructions. From these
CD4+ T lymphocytes, total RNA was extracted using
the Quiagen RNA tissue extraction kit (Quiagen, CA)
following the manufacturer’s instructions. The amount
and purity of the RNA were determined by spectrometry
at 260/280 nm. Total RNA was treated with DNase-I
(Fermentas, St. Leon-Rot, Germany), and the DNA copy
was synthesized using the RevertAid™ First Strand cDNA
Synthesis kit (Fermentas®, Thermo Fisher Scientific,
MA), according to manufacturer’s instructions.
For real time PCR, each 20 μl of mixture consisted of
0.5 μl of cDNA, 10 μl SYBR® Green PCR Master Mix
(Invitrogen, CA) and primers (0.4 μM each). The primer
sequences for CCR5, CXCR4, CCL3 (MIP-1alpha), CCL4Table 1 Primer pair sequences to detect expression of CCR5,
Primer name Target mRNA
CCR5F Exon 2a CCR5
CCR5R Exon 3 CCR5
CXCR4F Exon 1 CXCR4
CXCR4R Exon 2b CXCR4
CCL3F Exon 1 CCL3
CCL3R Exon 2/3 junction CCL3
CCL4F Exon 1 CCL4
CCL4R Exon 2 CCL4
CCL5F Exon 1 CCL5
CCL5R Exon 2 CCL5
CXCL12F Exon 2/3b junction CXCL12
CXCL12R Exon 3b CXCL12(MIP-1beta), CCL5 (RANTES), and CXCL12 (SDF-1)
were designed using the PrimerBlast Tool (NCBI web
site http://www.ncbi.nlm.nih.gov/). The target for each
of this set of primers is directed against exon junctions,
to avoid amplifying unspliced mRNA and/or genomic
DNA (Table 1); the same cycling profiles were used for
all sets of primers according to the SYBR® Green PCR
Master Mix instructions (50°C for 2 min, followed by
95°C for 10 min and 40 cycles of 95°C for 15 sec and
60°C for 1 min).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
amplification was used to normalize the RNA content of
the corresponding transcripts analyzed, and the re-
sult was expressed as relative units of transcription
(1.8[ΔCt Target gene-ΔCt GAPDH]). We included a melting
curve to confirm the specificity of the PCR product. All
real-time RT-PCR amplifications were performed using
the CFX96 real-time system and data analysis using the
software CFX Manager Version: 1.5.534.0511 (Bio-Rad,
Hercules, CA).
Determination of viral tropism
Predictions of co-receptor usage by HIV strains have
shown comparable results when performed using either
plasma virus or proviral sequences [36]. Genomic DNA
was isolated from PBMCs at months 0 and 12 of lova-
statin or placebo treatment; briefly, PBMCs were washed
twice with PBS and incubated overnight with White
Cells Lysis Buffer (Tris–HCl 0.02 M; EDTA 0.02 M;
NaCl 0.02 M; SDS 0.2%), and the genomic DNA was
isolated using the phenol–chloroform technique. The
amount and purity of the DNA samples were deter-
mined by spectrometry at 260/280 nm.
For proviral HIV-1 amplification, a nested PCR tech-
nique was used as previously described [37]. In the first
round, the reaction mixture of 25 μl included 0.5 μg of
genomic DNA, 0.4 nM of primer ED3, 0.4 nM of primerCXCR4, CCL3, CCL4, CCL5 and CXCL12
Primer sequence 5’-3’ Product size (bp)
TGATTTGCACAGCTCATCTGGCCA 169
CGGGCTGCGATTTGCTTCACATT
AGTGACGCCGAGGGCCTGAG 150
ACGGAAACAGGGTTCCTTCATGGA
CTCTGCAACCAGTTCTCTGCATCA 151
TGGTTAGGAAGATGACACCGGGCT
CTGCCTTCTGCTCTCCAGCG 134
GGAGCAGAGGCTGCTGGTCT
CCATGAAGGTCTCCGCGGCA 126
GTGGGCGGGCAATGTAGGCAA
CCCTTCAGATTGTAGCCCGGCTG 209
CTCATGGTTAAGGCCCCCTCCCC
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Thermo Fisher Scientific, MA). For the second round of
PCR, the same proportion of reactants was used for a re-
action of 50 μl including the primers ED31 and ED33. In
both PCR rounds, the reaction was subjected to a
prePCR: 94°C for 3 min, followed by 4 cycles at 94°C for
60 sec, and 55°C for 60 sec. Then, 32 PCR cycles at 94°C
for 15 sec, 55°C for 45 sec and 72°C for 60 sec, and a
final extension at 72°C for 7 min were performed.
An aliquot of 5 μl of the product of this nested PCR
were electrophoresed in 2% agarose, stained with SYBR
safe® (Invitrogen, CA), and visualized under UV light for
the detection of a band of 550 bp. The remaining prod-
uct was shipped to Macrogen (Macrogen Inc. Seoul,
Korea) to be sequenced using the ED31 and ED33
primers (forward and reverse sequences, respectively).
The contigs were assembled using the Seqman™ II
software version 5.01 (DNAStar Inc., Madison, WI) and
the sequences obtained, including the V3 loop portion
of gp120, served to predict the viral tropism using both
the clonal and clinical (CCR5 Δ32 genotype, viral load,
CD4+ T cell percentage and count, and CD8+ T cell
count) approximations, by means of the geno2pheno
(G2P) prediction algorithm (http://coreceptor.bioinf.
mpi-inf.mpg.de/index.php). The reported false positive
rate (FPR) was used as quantitative output and set to
20% [38].Data analysis
The overall activity of lovastatin vs. placebo in HIV-
infected individuals was established by intention to-treat
analysis. The frequency of positive cells and the mean
fluorescence intensity of CXCR4 and CCR5 on CD4+ T
lymphocytes at 0, 6 and 12 months after the intervention
were compared by Generalized Estimating Equations
(GEE) for repeated measurements, and informed as esti-
mated average changes (EAC) with 95% Confidence
Interval (CI). The frequency of positive cells and the
mean fluorescence intensity of CXCR4 and CCR5 on
CD4+ T lymphocytes from HIV negative controls at
days 0, 7, 30 and 45 were compared by the one way
Anova test for paired samples. The mean fluorescence
intensity of CXCR4 and CCR5 on CD4+ T lymphocytes
from asymptomatic HIV-1 infected patients vs. negative
controls was compared by the Student´s t-test. The
transcriptional levels of HIV co-receptors and their
ligands during 45 days of oral administration of statins
were compared by the one way Anova test for paired
samples. The Fisher exact test was used to compare the
frequency of X4 strains after one year of treatment in
placebo- vs. lovastatin-treated groups. In all the com-
parisons, a value of p < 0.05 was considered statistically
significant.Results
Lovastatin administration does not induce a shift in HIV
tropism
To determine the in vivo effect of lovastatin on the shift
in viral tropism in HIV-1 infected subjects, a total of 91
DNA samples corresponding to month 0, and of 72
DNA samples corresponding to month 12 after daily ad-
ministration of lovastatin, were amplified and sequenced.
However, only 61 samples were paired (from the same
patients at months 0 and 12) due to negative Env PCR
amplification or low quality of the sequence obtained;
52.5% vs. 47.5% of the samples were from lovastatin and
placebo patients, respectively. As shown in Table 2,
using the clinical model of analysis, at baseline level,
eight patients in the lovastatin treated group (18,1%) and
eight (17,0%) in the placebo group were found with X4
X4/R5 circulating virus, and all were predicted to belong
to the HIV-1 subtype B. A total shift in viral tropism of
15.6% in lovastatin-treated patients, and 20.7% in pla-
cebo patients was observed. The tropism shift from R5
to X4/X4R5 strains was 9.4% and 13.8% in lovastatin
and placebo treated patients, respectively (p = 0.6988).
Similar results were obtained using the clonal model of
analysis (Table 2). These results suggest that, in this
cohort of patients, the changes in use of the HIV-1 co-
receptor were due to the natural course of infection and
did not depend on the statin treatment.
Long-term use of statins does not affect the expression of
HIV co-receptors on CD4+ T cells
To define in vivo if the long-term administration of
lovastatin in HIV-infected patients reproduced a similar
regulatory effect on the expression of CCR5 as previ-
ously shown in vitro [25], a cohort of chronically HIV-1
infected patients enrolled in the LIVE clinical trial [35]
was examined. As shown in Table 3, one year adminis-
tration of lovastatin had no significant effect on the per-
centage of CD4+ T cells expressing CXCR4 or CCR5
(EAC = 1.1%, 95% CI = −6.3 to 8.5; and EAC = 2.8%, 95%
CI = −4.12 to 9.81, respectively). When the expression
level of CXCR4 and CCR5 was measured as the mean
fluorescence intensity (MFI) in the same population of
CD4 + T cells, the results were similar (EAC = −39.2,
95% CI = −91.1 to 13.5 and EAC = −5.7, 95% CI = −23.9
to 12.4, respectively). The same analysis performed in
the population of CD3-/CD4+ monocytes revealed no
significant changes in the expression level of CXCR4
and CCR5 (Table 4).
Since the surface expression of CXCR4 and CCR5
could be modulated by the immune activation observed
in HIV-1-infected patients, masking the effect of the
long-term administration of oral lovastatin on the ex-
pression of these molecules, the baseline level of CXCR4
and CCR5 expression was evaluated and compared in
Table 2 Prediction of co-receptor usage shift in proviral sequences from mononuclear cells
Total sequences obtained Lovastatin Placebo P value
(Fisher’s exact test)
Baseline 91 44/91 47/9 NA
(Number X4 X4/R5 strains) (8) (8)
12 months post treatment 72 38/72 34/72 NA
Number of paired sequences 61 32/61 (52.5%) 29/61 (47.5%) NA
Clinical model Total tropism shift 5/32 (15.6%) 6/29 (20.7%) 0.7426
R5 shift to X4 or X4R5 3/32 (9.4%) 4/29 (13.8%) 0.6988
Clonal model Total tropism shift 8/32 (25.0%) 5/29 (17.2%) 0.5411
R5 shift to X4 or X4R5 4/32 (12.5%) 4/29 (13.8%) 1.0
The geno2pheno (G2P) algorithm was used at the beginning of the study and 12 months post treatment with lovastatin (40 mg/day) or placebo in asymptomatic
HIV-1-infected patients. Isolation of peripheral blood mononuclear cells and proviral DNA preparation were as described in Methods. The G2P prediction algorithm
is available at http://coreceptor.bioinf.mpi-inf.mpg.de/index.php. NA, No applicable statistical analysis. At the baseline were found 8 individuals with X4 or X4R5
circulating strains in lovastatin treated group, and 8 individuals at placebo treated group.
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deed, as shown in Figure 1, the MFI for CXCR4 and
CCR5 was significantly higher in CD4+ T cells of HIV-1-
infected patients when compared to HIV negative indivi-
duals (median MFI CXCR4: 143 +/− 54 vs. 55 +/− 9 rela-
tive units, respectively, p < 0.0001; MFI CCR5: 76 +/− 36
vs. 37 +/− 26 units, respectively, p < 0.0001).
Effect of statins on HIV co-receptor expression in HIV
negative control subjects
Due to the differential expression of CXCR4 and CCR5
on resting CD4+ T cells of HIV-infected patients andTable 3 CXCR4 and CCR5 expression in CD4+ T lymphocytes
Parameter Time of treatment
% CD4+/CXCR4+ T cells Baseline
6 months post
12 months post
* EAC by treatment
MFI CXCR4 in CD4+/CXCR4+ T cells Baseline
6 months post
12 months post
EAC by treatment
% CD4+/CCR5+ T cells Baseline
6 months post
12 months post
EAC by treatment
MFI CCR5 in CD4+/CCR5+ T cells Baseline
6 months post
12 months post
EAC by treatment
CXCR4 and CCR5 expression levels were measured by flow cytometry at 0 (baseline
asymptomatic HIV-1-infected patients. * EAC, Estimated average changes with (95%
fluorescence intensity (in relative units).HIV negative adults, we explored the effect of daily oral
statins on the regulation of CXCR4 and CCR5 expres-
sion in HIV negative adults. At the different times of
observation of statin oral intake, there were not statisti-
cally significant differences in the frequency and MFI ex-
pression level of CXCR4 by blood CD4+ T cells, when
individuals receiving lovastatin or atorvastatin vs. con-
trols were compared (Table 5). Regarding the expression
of CCR5, only the administration of atorvastatin at
45 days of intake was associated with a significant in-
crease in the frequency of circulating CD4+ T cells ex-
pressing CCR5 (median day 7 = 11.1%; day 45 = 71.4%Placebo group (n = 43) Lovastatin group (n = 41)
(95% CI) (95% CI)
68.5 (48.2 - 90.2) 58.5 (32.0 - 87.1)
60.0 (41.0 - 82.0) 66.4 (43.2 - 90.0)
58.5 (33.4 - 87.5) 66.0 (40.1 - 87.0)
1.1% (−6.3 to 8.5)
157.4 (63.6 - 221.0) 118.7 (76.0 - 176.4)
132.9 (44.4 - 195.6) 117.0 (72.1 - 200.7)
132.1 (35.3 - 231.4) 116.1 (39.3 - 184.6)
−39.2 (−91.1 to 13.4)
17.8 (11.6 - 34.7) 23.6 (12.0 - 64.7)
19.2 (10.5 - 28.3) 26.0 (13.9 - 57.3)
21.5 (9.8 - 60.0) 22.5 (10.5 - 46.0)
2.84% (−4.1 to 9.9)
67.9 (50.0 - 94.9) 71.6 (54.1 - 90.6)
63.0 (42.7 - 99.0) 66.2 (44.0 - 98.7)
58.4 (33.5 - 107.3) 83.5 (42.1 - 125.5)
−5.7 (−23.9 to 12.4)
) 6 and 12 months post treatment with lovastatin (40 mg/day) or placebo in
CI) using a GEE model as defined in Data Analysis (see Methods); MFI, Mean
Table 4 Expression of CXCR4 and CCR5 in CD3-/CD4+ monocytes
Parameter Time of treatment Placebo group (n = 43)
(95% CI)
Lovastatin group (n = 41)
(95% CI)
% CD3-/CD4+/CXCR4+ monocytes Baseline 12.0 (3.0 - 23.0) 13.0 (4.0 - 21.0)
6 months post 14.0 (8.0 - 24.0) 16.5 (5.0 - 29.0)
12 months post 19.0 (10.5 - 37.5) 24.0 (10.0 - 58.0)
EAC by treatment −2.2% (−7.2 to 2.8)
MFI CXCR4 in CD3-/CD4+/CXCR4+ monocytes Baseline 196.8 (164.1 - 270.6) 192.2 (172.4 - 251.1)
6 months post 179.7 (28.6 - 236.8) 189.2 (127.1 - 304.9)
12 months post 149.6 (25.9 - 247.8) 86.2 (26.8 - 184.8)
EAC by treatment 8.7 units (−25.3 to 42.6)
% CD3-/CD4+/CCR5+ monocytes Baseline 2.5 (1.0 - 6.0) 2.0 (1.0 - 8.0)
6 months post 5.9 (1.3 - 16.5) 6.0 (2.3 - 12.2)
12 months post 6.0 (3.0 - 35.0) 12.0 (6.0 - 33.0)
EAC by treatment −0.99% (−5.1 to 3.1)
MFI CCR5 in% CD3-/CD4+/CCR5+ monocytes Baseline 148.2 (131.7 - 155.9) 146.9 (127.9 - 167.6)
6 months post 143.9 (38.1 - 168.2) 136.1 (48.9 - 171.0)
12 months post 104.4 (21.0 - 169.6) 133.9 (33.4 - 164.6)
EAC by treatment 11.4 units (−28.0 to 50.9)
CXCR4 and CCR5 expression levels were measured by flow cytometry at 0 (baseline) 6 and 12 months post treatment with lovastatin (40 mg/day) or placebo in
asymptomatic HIV-1 infected patients. * EAC, Estimated average changes with (95% CI) using a GEE model as defined in Data Analysis (see Methods); MFI, Mean
fluorescence intensity (in relative units).
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points of evaluation, in the CCR5 MFI level on CD4+ T
cells, at different times and with the different treatments
(ANOVA p ≥ 0.05) (Table 5).
In circulating monocytes, the administration of lova-
statin for 45 days was not associated with significant
modifications in the expression level of CXCR4 or CCR5
at the different times of evaluation (Table 6). In contrast,
the daily oral administration of atorvastatin was asso-Figure 1 Expression levels of CXCR4 and CCR5 in CD4+ T
lymphocytes. A: The mean fluorescence intensity (MFI) of CXCR4
and CCR5 was evaluated in CD4+/CXCR4+ and CD4+/CCR5+ T
lymphocytes respectively, by flow cytometry in peripheral blood
samples of 84 asymptomatic HIV-1-infected patients (HIV+) and 35
HIV seronegative volunteers (HIV-). Statistical comparison was made
using the Student’s t-test.ciated with a significant increase in both molecules on
peripheral blood monocytes, at days 30 and 45 of treat-
ment when compared to the values at day 7 (median of
cells expressing CXCR4, day 7 = 31.4%; day 30 = 72.3%;
day 45 = 69.3%; ANOVA p < 0.05; MFI of CXCR4 day 7
= 8.6; day 30 = 25.0; day 45 = 22.4; ANOVA p < 0.05).
Similar significant differences were observed for the
percentage of CCR5+ monocytes and their CCR5 MFI,
but only at day 45 of atorvastatin treatment (median of
cells expressing CCR5, day 7 = 14.9%; day 45 = 76.1%;
ANOVA p < 0.05; MFI of CCR5 day 7 = 6.2; day 45 =
26.8; ANOVA p < 0.05) (Table 6).
Effect of statins on the transcription level of HIV
co-receptors and their ligands in HIV negative controls
Daily administration of lovastatin or atorvastatin was
not associated with significant differences at the tran-
scription level of the CXCR4 and CCR5 co-receptors at
the different times of sampling (ANOVA p ≥ 0.05)
(Figure 2). Similarly, the transcriptional activity of CCL5
and CXCL12 in CD4+ T cells was not significantly
modified by the daily administration of lovastatin or
atorvastatin (ANOVA p ≥ 0.05) (Figure 3, lower panel).
In contrast, the administration of lovastatin was associ-
ated with a significant increase in the transcription of
CCL3 from 0 to day 30 and 45 of treatment (median
relative units of transcription = 8.85, 46.71 and 30.78
respectively, ANOVA p < 0.05), and in the transcription
level of CCL4 at day 30 (median relative units of
Table 5 Follow-up of CXCR4 and CCR5 expression in CD4+ T lymphocytes
CD4+ T lymphocytes Median (interquartile range) Comparison
by AnovaDay 0 Day 7 Day 30 Day 45
% CXCR4+ cells
Controls without statins (n = 7) 56.2 (22.1 - 66.9) 45.2 (22.9 - 69.5) 68.4 (55.5 - 82.5) 69.2 (61.2 - 97.3) NS
Lovastatin (n = 10) 54.5 (34.3 - 65.5) 30.9 (6.3 - 43.4) 66.1 (31.0 - 76.2) 63.8 (26.6 - 77.9) NS
Atorvastatin (n = 9) 45.6 (35.6 - 64.4) 37.1 (24.8 - 44.6) 67.9 (51.0 - 75.6) 18.6 (7.1 - 66.9) NS
MFI CXCR4 in CXCR4+ cells
Controls without statins (n = 7) 19.9 (6.6 - 29.1) 15.8 (6.6 - 34.8) 25.1 (19.8 - 43.9) 21.2 (16.7 - 29.3) NS
Lovastatin (n = 10) 16.5 (10.1 - 23.1) 8.9 (3.7 - 11.2) 16.3 (8.9 - 26.6) 20.4 (7.2 - 39.0) NS
Atorvastatin (n = 9) 14.1 (10.8 - 27.3) 11.7 (7.8 - 13.2) 23.1 (15.1 - 29.3) 11.8 (4.3 - 33.8) NS
% CCR5+ cells
Controls without statins (n = 7) 17.4 (10.9 - 26.9) 28.2 (7.9 - 52.75) 35.0 (26.8 - 56.7) 21.6 (17.6 - 25.9) NS
Lovastatin (n = 10) 13.3 (6.1 - 19.7) 9.4 (6.5 - 14.1) 14.1 (5.1 - 21.3) 18.1 (9.5 - 54.9) NS
Atorvastatin (n = 9) 10.4 (7.6 - 18.7) 11.1 (7.1 - 12.0) £ 13.5 (9.3 - 18.4) 71.4 (17.1 - 90.1) £ £ p < 0.05
MFI CCR5 in CCR5+ cells
Controls without statins (n = 7) 8.8 (5.8 - 10.6) 13.2 (11.1 - 19.4) 11.1 (9.6 - 17.1) 25.1 (13.1 - 29.1) NS
Lovastatin (n = 10) 23.0 (18.9 - 29.4) 21.9 (20.1 - 24.6) 29.4 (19.8 - 33.4) 24.1 (18.3 - 33.0) NS
Atorvastatin (n = 9) 25.9 (20.4 - 50.2) 21.9 (20.0 - 25.4) 36.0 (27.0 - 42.4) 25.1 (23.4 - 39.6) NS
HIV seronegative volunteers who received or not lovastatin (40 mg/day) or atorvastatin (20 mg/day) during 45 days, were evaluated at 0, 7, 30 and 45 days of
treatment by flow cytometry. NS, No statistically significant difference. £: Statistical difference obtained comparing day 7 and day 45 of treatment.
Table 6 Follow-up of CXCR4 and CCR5 expression in CD3-/CD4+ monocytes
Median (Interquartile range) Comparison by
AnovaCD3-/CD4+ monocytes Day 0 Day 7 Day 30 Day 45
% CXCR4+
Controls without statins (n = 7) 81.1 (61.0 - 83.5) 65.7 (41.9 - 85.4) 89.6 (55.6 - 93.0) 87.2 (60.7 - 91.2) NS
Lovastatin (n = 10) 48.6 (43.7 - 76.3) 34.8 (16.1 - 50.2) 69.7 (51.5 - 81.6) 57.7 (37.2 - 88.9) NS
Atorvastatin (n = 9) 40.2 (29.7 - 51.5) 31.4 (25.3 - 41.3) £. † 72.3 (53.6 - 82.4) £ 69.3 (36.3 - 89.3) † £ p < 0.05. † p < 0.05
MFI CXCR4 in CXCR4+ cells
Controls without statins (n = 7) 34.6 (17.1 - 37.7) 22.9 (10.6 - 58.4) 40.1 (16.6 - 58.4) 29.9 (13.7 - 33.5) NS
Lovastatin (n = 10) 16.3 (12.1 - 26.9) 9.2 (5.9 - 12.3) 19.5 (12.8 - 30.3) 13.4 (9.6 - 64.9) NS
Atorvastatin (n = 9) 10.6 (10.1 - 14.5) 8.6 (7.6 - 10.3) £. † 25.0 (13.5 - 28.2) £ 22.4 (9.7 - 57.9) † £ p < 0.05. † p < 0.05
% CCR5+
Controls without statins (n = 7) 56.8 (32.2 - 64.5) 52.9 (15.7 - 70.3) 60.9 (32.1 - 72.3) 79.6 (27.8 - 80.0) NS
Lovastatin (n = 10) 27.3 (21.6 - 41.5) 22.7 (7.8 - 26.9) 49.2 (24.0 - 61.8) 50.5 (18.9 - 73.7) NS
Atorvastatin (n = 9) 23.6 (17.0 - 55.7) 14.9 (8.5 - 21.3) † 55.7 (25.8 - 57.2) 76.1 (27.3 - 78.3) † † p < 0.05
MFI CCR5 in CCR5+ cells
Controls without statins (n = 7) 15.9 (9.0 - 19.4) 16.4 (6.0 - 25.2) 16.1 (10.2 - 29.0) 18.3 (8.0 - 20.7) NS
Lovastatin (n = 10) 8.6 (7.0 - 13.3) 7.1 (4.7 - 8.3) 12.7 (7.5 - 18.5) 11.8 (6.4 - 27.2) NS
Atorvastatin (n = 9) 7.1 (6.3 - 19.8) 6.2 (4.7 - 7.5) † 15.3 (8.0 - 16.1) 26.0 (8.0 - 29.5) † † p < 0.05
HIV seronegative volunteers who received or not lovastatin (40 mg/day) or atorvastatin (20 mg/day) during 45 days, were evaluated at 0, 7, 30 and 45 days of
treatment by flow cytometry. NS, No statistically significant difference. †: Statistical analysis performed comparing day 7 and day 45 of treatment; £: Statistical
difference obtained comparing day 7 and day 30 of treatment.
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Figure 2 Transcription levels of CXCR4 and CCR5 genes during lovastatin or atorvastatin treatment. Transcription levels of CXCR4 and
CCR5 in purified CD4+ T cells of adult HIV negative volunteers, during 45 days of oral administration of atorvastatin (20 mg/day; n = 9) or
lovastatin (40 mg/day; n = 10); the measurements were performed by real time PCR at baseline and on days 7, 30 and 45. Statistical comparisons
were performed using the One Way Anova test for paired samples.
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(Figure 3, upper panel); however, the administration of
atorvastatin was not associated with significant varia-
tions in the transcriptional activity of CCL3 and CCL4
(Figure 3, upper panel).
Discussion
In this investigation, evaluating a representative cohort of
chronic asymptomatic HIV-1-infected patients without re-
quirements to receive antiretroviral therapy, we demon-
strated that a daily oral administration of lovastatin duringFigure 3 Transcription levels of CCL3, CCL4, CCL5 and CXCL12 genes
CCL3, CCL4, CCL5 and CXCL12 in purified CD4+ T cells of adult HIV negativ
(20 mg/day; n = 9) or lovastatin (40 mg/day; n = 10); the measurements we
Statistical comparisons were performed using the One Way Anova test forone year did not result in significant modulation of CCR5
and CXCR4 expression on CD4+ T cells or CD4+ mono-
cytes. Also, in HIV negative individuals, the daily adminis-
tration of two different statins for 45 days did not lead to a
significant regulation of these molecules. These findings
suggest that long-term administration of statins, at doses
commonly used in clinical practice, does not have a sig-
nificant effect on modulating the expression of HIV-1 co-
receptors or their ligands (except for CCL3 and CCL4).
Previous results support the immunomodulatory effects
of statins in different inflammatory states [27,39-46].during lovastatin or atorvastatin treatment. Transcription levels of
e volunteers, during 45 days of oral administration of atorvastatin
re performed by real time PCR at baseline and on days 7, 30 and 45.
paired samples. (*): p value <0.05, considered significant.
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CCR5 and RANTES in CD4+ T lymphocytes by statins,
as well as their inhibition of infection by R5 strains of
HIV-1, was previously demonstrated [25]. These findings
highlighted the importance of verifying whether the ad-
ministration of statins modulated in vivo the expression of
such a receptor and its ligands, and if this treatment could
lead to the selection of X4 tropic strains of HIV-1 in
infected individuals. Several explanations might account
for the apparently contradictory data obtained in the
in vitro studies and our in vivo studies regarding the ac-
tions of statins. The incubation of CD4+ T cells with
statins in well plates allows the direct interaction of these
compounds with their cellular targets (HMG-CoA reduc-
tase), favouring the molecular effects expected of statins.
However, this might not be the case in vivo; considering
that HIV replication and immune activation are active on
secondary lymphoid organs (lymphoid nodes, mucosal
lymphoid tissues), several pharmacokinetic limitations
could hamper the effective biological activity of statins. In
particular, if the bioavailability of statins in lymphoid tis-
sues is deficient, then the immunomodulatory activities of
these compounds will be limited. Thus, statins with better
pharmacokinetic profiles would be more suitable to
achieve the effects observed in vitro, where direct adminis-
tration of statins to cells in culture overcomes the poten-
tial limitations derived from oral administration. It is also
possible that long-term administration of higher doses of
statins might be associated with better immunomodula-
tory effects, but the risks of adverse events and intolerance
also increase, questioning the beneficial balance of such
doses. Due that several factors could impact the outcome,
including drug dose, potency, treatment-time, further
investigations are needed in order to carefully demonstrate
that statins do not affect the expression of corecep-
tors and their ligands in HIV infected or uninfected
individuals.
The steady state expression of HIV-1 co-receptor mol-
ecules has been previously defined in HIV negative indi-
viduals, indicating that peripheral blood CD4+ naive T
cells (CD45RA+) express high levels of CXCR4, but
most of them are negative for CCR5; in contrast, most
memory CD4+ T cells express CCR5, becoming the
main target cells for efficient HIV-1 replication [47].
Also, in memory T cells, the expression of CCR5 may be
modulated by cell activation [17,48-50]. Other observa-
tions support the fact that the level of CCR5 expression
is associated with the infectious capacity of R5 strains of
HIV [51] and give us an important evidence that if we
regulate the expression of CCR5 it might act as a target
for HIV infection prevention and control of replication.
Additionally, HIV gp120 can acts in lymphocytes as
“viral chemokines” interacting with CCR5 or CXCR4,
and activating downstream signal proteins, induction ofion channel currents and Ca2+ flux, quantitatively differ-
ent to that induced by chemokines. These differences in
gp120 and chemokine-elicited Ca2+ flux can result in a
Long Terminal Repeat (LTR) activation, due to a pos-
sible differential transcription factor activation [52]. The
importance of the density of CD4 and of HIV CCR5 co-
receptor expression for efficient infection has been also
investigated in other cells different from human CD4+ T
cells. In CD4+ HeLa cells expressing minimal concentra-
tions of CCR5 on their surface, the infection by R5
strains of HIV occurred more efficiently during CCR5
expression concomitantly with a high level of CD4 ex-
pression, suggesting that a minimal number of CCR5
molecules are required when cell surface levels of CD4
reach a sufficient density [53]. Along the same line, epi-
demiological results associated the Δ32 CCR5 homozy-
gous genotype with protection against the acquisition of
HIV-1 [54-57], indicating that modulating CCR5 expres-
sion or function in HIV-infected individuals could help
control progression of HIV infection, as occurs with
maraviroc treatment; in despite of this, some Δ32 CCR5
homozygous individuals have become infected with
HIV-1, indicating that this genotype may not be fully
protective [58,59]. In our study, when compared with
HIV negative baseline values a significant increase in the
level of CCR5 expression on peripheral blood CD4+ T
cells from the HIV-1 infected individuals was observed,
which is in agreement with the uncontrolled chronic im-
mune activation characterizing this infection. Further-
more, expression of CXCR4 on these cells was also
significantly increased in infected individuals. Taken to-
gether, these facts suggest that generation of target cells
with higher expression of co-receptors requires niches
for persistent viral replication, and could be another
pathological event associated with chronic immune acti-
vation during HIV infection.
Increased CXCR4 expression in HIV-infected patients
is a remarkable finding, since enhanced expression of
CXCR4 has been associated with more risk of metastasis
in different types of cancers [60-64]; in fact, increased
severity of oncogenic processes in chronically HIV-
infected individuals has been previously documented
[65-71]. These findings highlight the importance of in-
vestigating the association between chronic immune ac-
tivation, enhanced expression of CXCR4 by different
cells and cancer progression, and metastasis during HIV
infection.
Regarding the expression of the CXCR4 and CCR5
ligands by purified CD4+ T cells of HIV negative adults,
we observed an increase in CCL3 and CCL4 transcripts
during lovastatin but not during atorvastatin treatment.
The increase in both transcripts might correspond to
the fact that the CCL3 and CCL4 genes are complexed
in a very close genomic region, and their expression is
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sible that differences in the chemical structure, potency
and molecular activity of lovastatin (natural statin) vs.
atorvastatin (synthetic statin) could be associated with
the apparently distinct immunomodulatory activities of
both statins.
Previous in vitro evidence indicated that statins were
not efficient in inhibiting the infection of CD4+ T cells
by X4 strains of HIV-1, in contrast to their capacity to
hamper the infection by R5 strains [25]; these observa-
tions generated the hypothesis that the long-term ad-
ministration of statins to HIV-1-infected patients could
lead to the selection of X4 strains, contributing to
accelerate the evolution of HIV infection to AIDS. The
frequency of the shift of R5 strains to X4 strains was
similar between placebo and patients treated with
lovastatin for one year, suggesting that the shifts in
co-receptor usage were due to the natural course of in-
fection, rather than to a selective process induced by
statins. This finding suggests that the therapeutic admin-
istration of statins in HIV-infected patients with lipid
disorders could be safe in terms of selecting X4 strains.
Although the role of the CCR5 and CXCR4 co-
receptors in HIV-1 infection is well established, little is
known regarding the regulation of their expression. Un-
derstanding these processes could facilitate the develop-
ment of new therapeutic interventions with a similar
mechanism of action as maraviroc. The investigation of
new compounds that block or modulate the expression
and function of HIV co-receptors must continue, since
they represent conserved host molecules rather than
viral proteins susceptible to continued mutations, mak-
ing them interesting targets for anti-viral therapies.
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